Other Events ·
Iovance Biotherapeutics, Inc. received marketing authorization from the Therapeutic Goods Administration of Australia…
IOVAIovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for the treatment of previously treated advanced melanoma. Additionally, stockholders-at-large at the Annual Meeting of Stockholders held on June 10, 2026, approved an amendment to the Certificate of Incorporation to increase authorized common stock from 500,000,000 to 650,000,000 shares. Iovance Biotherapeutics, Inc. is a biotechnology company that develops and commercializes cell therapies for cancer.